Bsf Enterprise Plc · LSE:BSFA
Bsf Enterprise — Investor Presentation (January 2024)
27 slides from Bsf Enterprise's investor presentation, January 2024
Slide 1: Unlocking the next generation of biotech solutions
Unlocking the next generation of biotech solutions. LON: BSFA (UK) | BSFAF: QBB (US) INVESTOR PRESENTATION Jan 2024 © 2024 BSF Enterprise PLC. All rights reserved.
Slide 2: Presentation Disclaimer
Presentation Disclaimer. The information contained in these slides and communicated orally to you, including the speech(es) of the presenter(s) and any materials distributed at or in connection therewith (together, the “Presentation”) is confidential. By reading the information contained in this Pre
Slide 3: Presentation Disclaimer (continued)
Presentation Disclaimer (continued). The Presentation has not been approved by the FCA and does not constitute, or form part of, an admission document, listing particulars, a prospectus or a circular relating to the Company, nor does it constitute, or form part of, any offer or invitation to sell or
Slide 4: Presentation Team
Presentation Team. § Joined BSF as Executive Director § Managing Director of BSF Enterprise after practising law for 30 years and CEO of 3D Bio-Tissues, BSF’s across Asia, Japan, Australia and wholly-owned subsidiary. China. § The first to 3D bio-print a human § Commercialised a variety of cornea an
Slide 5: Introducing BSF Enterprise
Introducing BSF Enterprise. BSF is a company focused on acquiring and growing biotech companies at the forefront of the health and food industry. § Our mission is to unlock the next generation of biotech solutions to transform the delivery of sustainable outcomes. § Founded in 2018 and listed on the
Slide 6: Our Mission
Our Mission. Animal husbandry continues to exacerbate the environmental crisis. We need to radically change how protein is produced. Tissue engineering can address challenges in carbon reduction by replacing organic tissue with lab-grown equivalents. Our mission is to unlock the next generation of b
Slide 7: Biotech that addresses real challenges
Biotech that addresses real challenges. Tissue engineering that replaces animal tissue with lab- grown scaffold-free bio-equivalents such as: Protein Chicken Beef Pork § Muscle (cultured meat) § Skin (lab grown leather) § Corneas (medical device) Impact on Livestock agriculture is currently responsi
Slide 8: Our growth strategy
Our growth strategy. Our growth strategy is founded on three pillars: Acquire Commercialise Develop Biotechnology Cell Culture Cell Biology & Bioengineering & Tissue Culture & Physiology ■ First acquisition of 3D Bio-Tissues made on IPO in early 2022. ■ Current focus is on developing and commerciali
Slide 9: The BSF Enterprise Group
The BSF Enterprise Group BSF Enterprise (Hong Kong) Ltd | 09 © 2024 BSF Enterprise PLC. All rights reserved.
Slide 10: World leading scaffold-free tissue engineering solutions
World leading scaffold-free tissue engineering solutions. www.3dbiotissues.com
Slide 11: Our journey
Our journey. 15 years of academic study funded by about £5M UK Company spun out from IP and development of First 100% lab grown meat funding. Newcastle University City-MixTM. developed. 2018. Ideas and research into a Focus on meat and Commercial sale of City- new form of tissue Moved to The Biosphe
Slide 12: A platform process
A platform process. ENGINEERED BY FINE-TUNED NANO-STRUCTURE CITY-MIX™ LAB GROWN TISSUES – BIOLOGY PRODUCED BY CELLS “CELL BOOSTER” 100% NATURAL, SCAFFOLD-FREE | 11 © 2024 BSF Enterprise PLC. All rights reserved.
Slide 13: What's Scaffold-Free?
What’s Scaffold-Free? § Cultured meat or leather products require structure as well as cells to give the tissue function (texture, mouth-feel, strength) § Structure has previously been generated using synthetic or plant-based scaffolds § However, using such scaffolds does not result in a natural fee
Slide 14: The UK's First Lab-Grown Steak
The UK’s First Lab-Grown Steak. • On 27 January 2023 3DBT produced the UK’s first lab-gown fillet of 100% meat. Further technical test May 26th 2023 • Porcine cells were cultivated in 3DBT’s patented City- Mix™ to produce a fillet of pork and pork strip • Represents an important scientific breakthro
Slide 15: City-Mix Supplements – An Effective Cell Booster
City-Mix™ Supplements – An Effective “Cell Booster” § Patented non-toxic formulation (zero toxicity). § Inert, food-safe, chemically-defined. § Facilitates macromolecular crowding in culture, which: § Creates pockets of higher concentration of soluble growth factors. § Improves enzyme kinetics. § Pr
Slide 16: Product Pipeline and Commercialisation Strategy
Product Pipeline and Commercialisation Strategy. 3DBT’s City-MixTM a B2B License evaluation of TE applications for lab- TE applications for Substitute corneas as a product under evaluation 3DBT’s lipopeptide EtsylTM grown skin and out-licensed cultured meat and out- medical device and out- by >20 cu
Slide 17: 3D Bio Tissues Developments
3D Bio Tissues Developments. • New Partnerships with Qkine Ltd, and New Harvest to expedite the creation of affordable cultivated meat • Signed distribution partners covering Germany, Austria, Switzerland, Australia, New Zealand and United Kingdom. • Progressing partnerships with established food ma
Slide 18: Kerato corneal products
• Kerato will address the global shortage of donor human corneas for medical and research applications • Developing two applications: Implantable Medical Device CITY-MIX™ SALES & Ocular Toxicity Testing Platform • Kerato will seek to accelerate the transition of 3DBT's advanced corneal products into
Slide 19: Cultured Meat at Scale
Cultured Meat at Scale • Solving critical issues in cultured meat production. • 3DBT has entered a Joint Venture with CellulaRevolution Ltd to manufacture cultivated meat at scale. • CMT will combine CellRev's bioprocessing expertise with 3DBT’s tissue engineering know how and City- Mix™ animal-free
Slide 20: BSF Enterprise (Hong Kong) Ltd
BSF Enterprise (Hong Kong) Ltd § Established presence in Hong Kong to access to the Greater China market. § China alone consumes more than 100 million tons of meat, more than a quarter of global meat consumption. § 3DBT is developing a distribution network in this region, engaging with biotech compa
Slide 21: Lab Grown Leather
Lab Grown Leather • In 2023, 3DBT bio-engineered samples of animal skin tissue. • BSF has engaged with a number of companies within the leather industry in the UK and abroad establishing Proof of Concept (PoC) contracts. • Now developing a separate business – Lab Grown Leather - to scale up technica
Slide 22: BSF Enterprise PLC (Board of Directors)
BSF Enterprise PLC (Board of Directors). Min Yang Geoffrey Baker Dr. Che Connon Dennis Ow Graham Duncan Chair Director Managing Director Non-Executive Director CFO § A wealth of experience § A qualified lawyer in § The first to 3D bio-print a § Formerly a business § A Chartered Accountant spanning o
Slide 23: Summary
Summary. Investment in BSF provides exposure to the compelling and rapidly growing industrial tissue engineering market IP protection: City-Mix™ media boosts cell growth, whilst tissue templating produces highest quality animal tissue 1 Highly differentiated: City-Mix™ is chemically defined; tissue
Slide 24: Investor Relations Information
Investor Relations Information. Shareholders % Holdings ADVISORS BSF Angel Funding LTD 16.13 Che Connon 12.55* Brokerage Shard Capital Brokers Newcastle University Holdings Ltd 6.72 Jarvis Inv Mgmt Ltd 6.58 UK Legal Hargreaves Lansdown plc 6.49 RPC Advance Plan Investments Ltd 4.86 Communications WB
Slide 25: BSF Press Coverage (continued)
BSF Press Coverage (continued). | 25 © 2024 BSF Enterprise PLC. All rights reserved.
Slide 26: Industry Press Coverage
Industry Press Coverage. | 26 © 2024 BSF Enterprise PLC. All rights reserved.
Slide 27: LON:BSFA (UK) | BSFAF:QBB (US)
LON:BSFA (UK) | BSFAF:QBB (US) www.bsfenterprise.com © 2024 BSF Enterprise PLC. All rights reserved.
BSF Enterprise — Investor Presentation (January 2024) on 6ix